Stock Analysis of Piramal Pharma Ltd. (PPLPHARMA) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code PPLPHARMA
Close 183.44
Change -2.86 / 1.54 %
Volume 2182.62 K
Vol Change -35227.00 / 1.59 %
IndustryDrugs & Pharma
SectorHealthcare
Type - F&O F&O Stock List
TSR Strength Index
Technical StrengthStrong Bearish
Growth Index Poor Growth Stock
Value Index No Significant Value
Profitability Index Very Low Profitability Stock
Stability Index No Significant Stability


Fundamental View of Piramal Pharma Ltd.
PE (TTM)

248.04

Very Poor
Price / Book

3.04

Very Poor
Price / Sales

2.66

Poor
Piotroski F Score

7.0

Very Good
Market Cap

24244.90 (Cr)

Enterprise Value

28633.23 (Cr)

ROA (TTM)

0.636

Poor
ROE (TTM)

1.23

Poor
Net Margin (TTM)

1.07

Poor
Revenue

11.99 %

91511.80 M
Net Profit

411.39 %

911300 K
Debt to Equity

0.585

Good
Altman Z Score

2.92

Indecisive
Quick Ratio

0.925

Not Good
Cash Ratio

0.133

Poor


Highs/Lows of Piramal Pharma Ltd.
PeriodOld priceStock ReturnNifty 50HighLowHigh DateLow Date
One Week192.754.83 % 1.78 % 197.20182.8025-Aug-2529-Aug-25
Two Week190.043.47 % 0.830 % 197.20182.8025-Aug-2529-Aug-25
One Month205.6110.78 % 1.59 % 206.00182.8030-Jul-2529-Aug-25
Three Month205.0910.56 % 1.64 % 220.85182.8017-Jul-2529-Aug-25
Six Months189.893.40 % 10.41 % 240.95182.8003-Apr-2529-Aug-25
One year182.510.510 % 2.88 % 307.90181.7306-Nov-2414-Feb-25
Two year99.5584.27 % 26.28 % 307.9087.5006-Nov-2426-Oct-23


Technical View of Piramal Pharma Ltd.
RSI

33.15

Neutral
MACD

-3.43

Bearish
ADX

29.56

Bearish
Super Trend

200.19

Mild Bearish
Williams %R

-95.56

Mild Bullish
CCI

-210.20

Mild Bearish


EMA 5

187.64

Strong Bearish
EMA 15

191.00

Strong Bearish
EMA 50

197.54

Strong Bearish
EMA 100

203.26

Strong Bearish
SMA 100

204.44

Strong Bearish
SMA 200

219.32

Strong Bearish
SMA 5 / 20

188.93 / 191.08

Mild Bearish
SMA 15 / 50

190.60 / 198.80

Strong Bearish
SMA 50 / 200

198.80 / 219.32

Strong Bearish




Charts of Piramal Pharma Ltd.


Returns of Piramal Pharma Ltd. with Peers
Period / StockPPLPHARMASYNGENEERISPFIZER
1 Week-4.83%-6.22%1.78%-9.04%
1 Mth-10.78%-12.02%0.452%-2.29%
3 Mth-10.56%-3.37%11.42%-7.69%
6mth-3.40%-4.06%52.20%27.29%
1 Year0.510%-26.69%34.08%-13.44%
2 Year84.27%-18.56%123.25%34.30%
5 Years-28.25%247.66%8.78%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Piramal Pharma Ltd. with Peers
Ratio / StockPPLPHARMASYNGENEERISPFIZER
PE248.0449.6763.3229.17
P/B3.045.527.606.04
ROA0.6367.975.5017.60
ROE1.2311.1613.9920.70
Debt To Equity0.5850.03580.8680.0097
Revenue91511.80 M
11.99 % 		36424.00 M
4.41 % 		28936.40 M
44.02 % 		22813.50 M
4.02 %
Net Income911300 K
411.39 % 		4962.00 M
2.71 % 		3518.40 M
10.24 % 		7676.00 M
39.23 %


Technicals of Piramal Pharma Ltd. with Peers
Technical / StockPPLPHARMASYNGENEERISPFIZER-
ADX29.5616.6631.7627.70
CMF-0.398-0.111-0.056-0.078
MFI54.1341.8472.7983.48
RSI33.1535.1559.8941.45
MACD Abv SignalFalseFalseTrueFalse
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MAFalseFalseTrueTrue-


About : Piramal Pharma Limited

Address : Piramal Ananta, Mumbai, India, 400 070
Tel : 91 22 3802 3000
URL : https://www.piramalpharma.com
Code : PPLPHARMA, ISIN : INE0DK501011, Exchange : NSE, Country : India
Fiscal Year End : March
Employee Count : 5476

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Quick Overview of Birds Eye View